To obtain the subject new compound sowing more raised bioavailability than that of an already-known compound, useful for treating bodily disorders caused by deficiency of growth hormone.
This compound is shown by formula I [R1 is H or a 1-6C alkyl; R2 is a 1-6C alkyl; (a) and (b) are each 1 or 2; G and J are each a group of formula II or formula III (R27 to R31 are each H, a halogen or the like); D is a group of formula IV (R7 to R10 are each H, a 1-6C alkyl which may be substituted with amino or the like; (n) and (m) are each 0-3; (o) and (p) are each 0 or 1; M is O, S or the like); E is a group of the formula, CONR12R13 (R12 is H or a 1-6C alkyl which may be substituted with a halogen or the like; R13 is a 1-6C alkyl which may be substituted with hydroxy or the like)] such as (4-(1-aminocyclobutyl)but-2-enoic acid ((1R)-1-(((1R)-1-(1-methylcarbamoyl-2- phenylethyl)methylcarbamoyl)-2-(2-naphthyl)ethyl)methylamide. The compound of formula I is obtained, for example, by starting from ethyl chloroformate and 3-tert-butoxycarbonylamino-3-methylbutanoic acid.
PESCHKE BERND
LAU JESPER
LUNDT BEHREND FRIEDRICH
ANKERSEN MICHAEL
WATSON BRETT
MADSEN KJELD
